Clinical Trials Logo

Diabete Type 2 clinical trials

View clinical trials related to Diabete Type 2.

Filter by:

NCT ID: NCT04485845 Recruiting - Metabolic Syndrome Clinical Trials

Metformin Versus Vildagliptin in Reducing Risk of Metabolic Syndrome Complications Progression

Start date: November 1, 2019
Phase: Phase 4
Study type: Interventional

Several crosssectional and prospective studies have shown that metabolic syndrome and its related components are associated with both prevalent and incident CKD . Although the mechanisms for these cardiovascular benefits of Metformin and vildagliptin remain unclear, they extend well beyond glycemic lowering, and therefore are probably best considered diverse "cardiometabolic" pharmaceuticals rather than simply type 2 diabetes drugs. Metformin and vildagliptin have known vasculoprotective actions, but the value of these drugs on drug-naïve diabetic patients during 24 week use warrants investigation. The investigator's purpose was to observe their effects on weight control, Cardiometabolic Risk Factors, Metabolic Syndrome risk, and diabetic nephrooathy Progression.

NCT ID: NCT03341793 Recruiting - Diabete Type 2 Clinical Trials

Impact of Changes in Muscle Secretome in the Remission of Type 2 Diabetes Mellitus Induced by Bariatric Surgery

MYDIASECRET
Start date: November 14, 2017
Phase: N/A
Study type: Interventional

Bariatric surgery is recognized as a therapeutic modality of type 2 diabetes. The mechanisms of this remission of diabetes remain poorly understood. The aim of our research is to characterize the changes in muscle secretome induced by bariatric surgery and to determine their role in improving the insulin sensitivity of skeletal muscle and insulin secretion by the B cell responsible for the remission of diabetes.